We Chelsea about That . . .
Phase III Endpoint Switcheroo: Proceed at Your (Lesser?) Risk
By Randy Osborne
Chelsea Therapeutics Inc.'s earnings-call news last week that the firm is asking the FDA to allow an endpoint change in the still-blinded, second Phase III test with droxidopa for low blood pressure caused some Wall Street ripples, and sparked speculation on the wisdom of such a move.